BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 12926050)

  • 1. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
    Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
    Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF.
    Xia L; Paik A; Li JJ
    Cancer Res; 2004 Jan; 64(1):221-8. PubMed ID: 14729628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of p53 and MDM2 activity by MTBP.
    Brady M; Vlatkovic N; Boyd MT
    Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.
    Stommel JM; Wahl GM
    EMBO J; 2004 Apr; 23(7):1547-56. PubMed ID: 15029243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
    Lin J; Tang H; Jin X; Jia G; Hsieh JT
    Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
    Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
    Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
    Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
    Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin.
    Smith ML
    Breast Cancer Res Treat; 1999 Nov; 58(2):99-105. PubMed ID: 10674873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
    Gudas JM; Nguyen H; Klein RC; Katayose D; Seth P; Cowan KH
    Clin Cancer Res; 1995 Jan; 1(1):71-80. PubMed ID: 9815889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
    Traidej M; Chen L; Yu D; Agrawal S; Chen J
    Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A possible role of p73 on the modulation of p53 level through MDM2.
    Wang XQ; Ongkeko WM; Lau AW; Leung KM; Poon RY
    Cancer Res; 2001 Feb; 61(4):1598-603. PubMed ID: 11245471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.